BioSpace News Archive

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Blocking the action of calcium signals in immune cells suppresses the most common form of asthma, but without compromising the body’s defenses against flu viruses, a new study finds.

ORIC Pharmaceuticals, Inc. announced that on October 3, 2022, ORIC granted a total of 116,560 non-qualified stock options and 19,435 restricted stock units to five new non-executive employees who began their employment with ORIC in September 2022.

Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing, and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), today announced that Neil Clendeninn, MD, PhD, joined as Chief Medical Officer.

Sensient Technologies Corporation will hold its conference call to discuss 2022 third quarter results at 8:30 a.m. CDT on Friday, October 21, 2022.

XORTX Therapeutics Inc. announces the closing of an underwritten public offering of: 1,400,000 common share units, with each Common Share Unit consisting of one common share, no par value, and one warrant to purchase one common share at a public offering price of US$1.00 per Common Share Unit.